Skip to main content
TipRanks
Go Ultimate75% OFF

Arrowhead Pharmaceuticals (HDP1) AI Stock Analysis

1 Followers
DE:HDP1

Arrowhead Pharmaceuticals

(XETRA:HDP1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Commercial traction and market accessGrowing prescriber adoption alongside broad payer coverage provides an emerging commercial foundation for REDEMPLO. This improves the potential for recurring product revenue, strengthens access to target patients, and supports a durable transition from development-stage science toward a commercial operating model.
Negative Factors
Severe profitability deteriorationThe sharp loss and elevated operating base show that current commercial revenue is not yet sufficient to fund development and launch investments. Unless revenue scales materially or spending becomes more efficient, ongoing losses could constrain capital allocation and increase dependence on external financing.

Arrowhead Pharmaceuticals (HDP1) vs. iShares MSCI Germany ETF (EWG)

-25%0%25%50%75%100%125%DE:HDP1+23.36%EWG+9.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 6.75B
Dividend Yield
―
Average Volume (3M)
298
Price to Earnings (P/E)
-9.4
Beta (1Y)
0.83
Revenue Growth
-49.15%
EPS Growth
-5757.84%
Country
Germany
Employees
1,059
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Arrowhead Pharmaceuticals Business Overview & Revenue Model

Company Description

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. Th...

Arrowhead Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q4-2026)|% Change Since:-1.17%|Next Earnings Date:Feb 10, 2027
Earnings Call SentimentPositive

The call was predominantly optimistic, with strong REDEMPLO prescription and prescriber growth, broadening payer coverage, positive pivotal sHTG efficacy results, clinical validation of new RNAi delivery capabilities and improved financing terms. These positives were tempered by a substantial net loss, lower year-over-year revenue, higher operating expenses, ongoing prescription-to-paid-claim conversion work, regulatory and launch uncertainty for sHTG, glycemic-control findings and unresolved safety and dosing questions for ARO-DIMER-PA.

Positive Updates

REDEMPLO Prescription Growth
Fiscal fourth-quarter new-to-brand prescriptions grew 63% from the prior quarter end to 950 as of September 30, 2026, and exceeded 1,250 cumulatively afterward. The recent prescription run rate increased to approximately 50 to 60 per week from the previously cited 20 to 30 per week.

Negative Updates

Significant Fiscal-Year Net Loss
Fiscal year 2026 net loss attributable to Arrowhead was $724.2 million, or $5.11 per share, compared with a net loss of $1.6 million, or $0.01 per share, in fiscal year 2025. Excluding a one-time $215 million priority review voucher expense, the fiscal 2026 net loss would have been approximately $509 million.

Company Guidance

Management is preparing for a potential U.S. launch of REDEMPLO in sHTG in the second quarter of 2027, subject to successful FDA review and approval, with the sNDA expected to receive a PDUFA date over the next 50 days or so under STAR’s 6-month priority review framework; it continues to see $3 billion to $4 billion in annual U.S. sales over time in sHTG, targeting an initial population of almost 1 million people, including patients with triglycerides at or above 880 milligrams per deciliter or above 500 milligrams per deciliter with a prior history of pancreatitis, supported by a current U.S. wholesale acquisition cost of $45,000 per patient per year and more than 20,000 health care professionals identified as likely sHTG treaters. The company expects to report additional obesity data before the end of the year, additional ARO-DIMER-PA data around mid-2027, the 70 Phase III readout in HoFH in the second half of 2027, a zodasiran NDA filing by the end of 2027, and initial patient data from ARO-MAPT in the second half of 2027; it is targeting CTAs for 2 wholly-owned CNS candidates around end of 2026 or early '27 and additional CNS clinical entries by the end of 2027. Management said it is too early to provide financial guidance.

Arrowhead Pharmaceuticals Risk Analysis

Arrowhead Pharmaceuticals disclosed 67 risk factors in its most recent earnings report. Arrowhead Pharmaceuticals reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Arrowhead Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:HDP1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SRPTSRPT60Neutral$1.72B178.561.04%―-18.95%59.85%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
NTLANTLA49Neutral$1.36B-2.90-64.73%―-8.07%21.55%
STOKSTOK46Neutral$1.75B-7.04-67.30%―-86.28%-634.38%
DYNDYN44Neutral$3.22B-4.73-69.73%――0.69%
IONSIONS42Neutral$4.84B-8.75-120.44%―-0.79%-106.48%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:HDP1IONSSRPTNTLASTOKDYNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:HDP1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:HDP1Arrowhead Pharmaceuticals, Inc.42.998.3624.14%
IONSIonis Pharmaceuticals Inc.29.06-44.20-60.33%
SRPTSarepta Therapeutics Inc.16.07-1.47-8.38%
NTLAIntellia Therapeutics Inc9.701.2214.39%
STOKStoke Therapeutics26.68-0.27-1.00%
DYNDyne Therapeutics, Inc.17.16-3.08-15.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.